Some items may require FREE registration to access.
If a URL does not work, please let me know so that I can fix it.



Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimer's and Parkinson's Diseases at AAN Annual Meeting

http://sev.prnewswire.com/biotechnol...1052009-1.html

OMAHA, Neb. and HOUSTON, May 11 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTCBulletinBoard: TBIO) and Power3 Medical Products, Inc. (OTCBulletinBoard: PWRM) , announced the clinical introduction of the NuroPro(R) AD and NuroPro(R) PD tests for Alzheimer's and Parkinson's disease at the 2009 American Academy of Neurology meeting in Seattle, WA. The NuroPro tests help clinicians distinguish patients with Alzheimer's and Parkinson's diseases from "normal" individuals and patients with other neurological disorders. The tests, developed by Power3, are a panel of blood serum protein biomarkers evaluated by biostatistical analysis to predict the probability a patient has neurodegenerative disease. This information will help physicians make earlier diagnoses and recommend appropriate follow-up and treatment options for their patients.


Long-term Effect of Initiating Pramipexole [Mirapex] vs Levodopa in Early Parkinson Disease

Parkinson Study Group CALM Cohort Investigators

Arch Neurol. 2009;66(5):563-570. Vol. 66 No. 5, May 2009Clinical Trials
http://archneur.ama-assn.org/cgi/content/short/66/5/563

Objective To compare the long-term outcomes of subjects initially treated with pramipexole dihydrochloride with those of subjects initially treated with levodopa in the Comparison of the Agonist Pramipexole With Levodopa on Motor Complications of Parkinson's Disease (CALM-PD) trial.

Design Up to 2 years of open extended follow-up of the CALM-PD subjects.

Setting Academic movement disorders clinics at 22 sites in the United States and Canada.

Patients Patients with early Parkinson disease (N = 301) who required dopaminergic therapy to treat emerging disability were enrolled between October 1996 and August 1997, a subset of whom consented to extended follow-up until August 2003 (n = 222).

For balance of study, click on the link above.


Researchers Link Oxidation of Potassium Channel in Cells to Loss of Sensory Function in Aging

Keywords
POTASSIUM CHANNEL SENSORY LOSS AGING ALZHEIMER'S PARKINSON'S

http://www.newswise.com/articles/view/552291/?sc=rssn

Description
Researchers at UMDNJ-Robert Wood Johnson Medical School are one step closer to determining how human cells can be protected against the affects of age-related neurodegeneration including Alzheimer’s and Parkinson’s disease. The findings, published this past month in Nature Neuroscience, link the oxidation of potassium channels, which control a variety of cell functions and are essential to neuronal function, to the loss of neuronal function in aging.


Distinguishing between sadness and depression

Posted: 01:57 PM ET, By Caitlin Hagan, CNN Medical Associate Producer
http://pagingdrgupta.blogs.cnn.com/2...nd-depression/

One of my good friends recently went through an unexpected breakup. I’ll spare you the details but suffice it to say it was not a pretty situation. But my friend is a strong person. A little time being sad and a few girls’ nights were all she thought she needed to bounce back and feel happy again. But months went by and things didn’t get any easier. I remember talking to her one night over dinner, when her sadness and anger gave way to frustration. She couldn’t wait to stop being sad, she said. When would she be happy again?



Do parkinsonian patients have trouble telling lies? The neurobiological basis of deceptive behaviour

http://brain.oxfordjournals.org/cgi/...ull/132/5/1386

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Summary
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Funding
References